FDA Grand Rounds

Nanotechnology: Over a Decade of Progress and Innovations at FDA

Thursday, August 13, 2020

12:00 p.m. - 1:00 p.m. EST

Webcast Only

Register here for webcast (public attendees and FDA staff)

CE Credit Available

Presented by:

Anil K. Patri, Ph.D.

Chair, Nanotechnology Task Force

Director, Nanocore, NCTR/FDA

About the Presentation:

Nanotechnology is the control of matter at the nanoscale, where unique phenomena and unusual properties enable novel applications. Nanomaterials are incorporated in many FDA regulated products, utilizing the unique advantages they offer, such as increased sensitivity of detection of biomarkers for early disease detection and diagnosis, generation of safer drug formulations and novel medical devices. Anticipating an increase in submissions to FDA of products that involve the application of nanotechnology, the FDA launched the Nanotechnology Task Force (NTF) in 2006.

This Grand Rounds is aimed at presenting the Nanotechnology Task Force report on the progress FDA has made in nanotechnology since 2007. The presentation includes the basics of nanotechnology, highlight the facilities, regulatory science research, guidance documents, standards, domestic and international collaborations, and emerging challenges in regulatory science.

What you’ll learn from this FDA Scientist:

How nanomaterials are incorporated into FDA products
The advantages of using nanomaterials
How nanotechnologies can be used to advance public health during emerging threats